PUBLISHER: The Business Research Company | PRODUCT CODE: 1588830
PUBLISHER: The Business Research Company | PRODUCT CODE: 1588830
Gonadotropin-Releasing Hormone (GnRH) Agonist Global Market Report 2024
Gonadotropin-releasing hormone (GnRH) agonists are synthetic drugs that mimic the action of natural GnRH, stimulating the pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These agents are employed to manage hormonal imbalances by regulating hormone levels and are particularly valuable in fertility treatments, where they help control and prevent premature ovulation during procedures such as in vitro fertilization.
The main types of GnRH agonists include leuprorelin, goserelin, taltirelin, histrelin, and others. Leuprorelin, a synthetic hormone, is used to treat prostate cancer, endometriosis, and uterine fibroids by decreasing hormone production. It is administered via monthly or quarterly injections and comes in various formulations, such as injectables, implants, oral tablets, and nasal sprays. Distribution channels for these medications include hospital pharmacies, retail pharmacies, and online pharmacies. Applications of leuprorelin encompass prostate cancer, breast cancer, endometriosis, uterine fibroids, precocious puberty, and fertility treatments, with end users including hospitals, specialty clinics, ambulatory surgical centers (ASCs), and other medical facilities.
The gonadotropin-releasing hormone (GnRH) agonists market research report is one of a series of new reports from The Business Research Company that provides gonadotropin-releasing hormone (GnRH) agonists market statistics, including the gonadotropin-releasing hormone (GnRH) agonists industry global market size, regional shares, competitors with the gonadotropin-releasing hormone (GnRH) agonists market share, detailed gonadotropin-releasing hormone (GnRH) agonists market segments, market trends, and opportunities, and any further data you may need to thrive in the gonadotropin-releasing hormone (GnRH) agonists industry. These gonadotropin-releasing hormone (GnRH) agonists market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gonadotropin-releasing hormone (GnRH) agonist market size has grown steadily in recent years. It will grow from $3.99 billion in 2023 to $4.1 billion in 2024 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to increasing awareness and diagnosis of hormonal disorders, a rising prevalence of hormone-related diseases, a growing incidence of prostate cancer, heightened awareness about hormone therapy, and a greater demand for long-term safety and efficacy.
The gonadotropin-releasing hormone (GnRH) agonist market size is expected to see steady growth in the next few years. It will grow to $4.6 billion in 2028 at a compound annual growth rate (CAGR) of 2.9%. The growth in the forecast period can be attributed to increased awareness and early diagnosis, rising healthcare expenditure, growing use of GnRH agonists in fertility treatments, a heightened demand for personalized medicine, and more research funding and grants. Major trends expected include advancements in drug delivery systems, progress in oncology and reproductive medicine, a growing demand for hormone therapy options, increased research and development efforts, and the rise of long-acting formulations.
The rising prevalence of hormone-related diseases is anticipated to drive the growth of the gonadotropin-releasing hormone (GnRH) agonist market in the coming years. Hormone-related disorders are medical conditions resulting from imbalances or malfunctions in the endocrine system, which regulates hormone production. These disorders include conditions such as diabetes, hyperthyroidism, and prostate cancer. Factors such as environmental influences, obesity, metabolic syndrome, genetics, and an aging population contribute to the increasing incidence of these diseases. GnRH agonists help manage hormone levels and offer a targeted approach to treating issues associated with hormonal imbalances and hormone-dependent conditions. For instance, a report by the Centers for Disease Control and Prevention (CDC) in June 2024 revealed that in 2021, there were 236,659 new cases of prostate cancer in the U.S., with 33,363 deaths from the disease in 2022. Thus, the growing prevalence of hormone-related diseases is fueling the demand for GnRH agonists.
Companies in the GnRH agonist market are focusing on developing advanced androgen deprivation therapy (ADT) drugs to improve treatment efficacy and precision for hormone-sensitive cancers. ADT drugs, including GnRH analogs, work by reducing or eliminating androgen levels, thereby slowing or stopping the growth of hormone-sensitive cancers. For example, in January 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, introduced Relugolix under the brand name Rexigo. This is India's first and only once-daily oral therapy for testosterone suppression in advanced prostate cancer, eliminating the need for injectable treatments. Relugolix, a globally recognized active ingredient, provides rapid testosterone suppression. Rexigo is 50% more affordable than existing injectable treatments for advanced prostate cancer in India, marking a significant advancement in prostate cancer care by offering a safe, effective, and convenient treatment option for patients and healthcare providers.
In February 2022, Debiopharm, a Switzerland-based manufacturer of GnRH agonists, partnered with Aspen Holdings to launch Trelstar in South Africa. This collaboration aims to introduce Trelstar as a treatment for locally advanced and metastatic hormone-dependent prostate cancer. The partnership is set to deliver a high-quality oncology product, significantly enhancing prostate cancer treatment in the region and improving the overall treatment landscape for affected patients. Aspen Holdings, based in South Africa, provides specialty and generic pharmaceuticals.
Major companies operating in the gonadotropin-releasing hormone (GnRH) agonist market are Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Sandoz Group AG, Ipsen Pharma, Aurobindo Pharma Limited, Cipla Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Ferring Pharmaceuticals, Amneal Pharmaceuticals Inc., Endo International plc, Lupin Limited, Gland Pharma Limited, Glenmark Pharmaceuticals Ltd., Zydus Lifesciences Limited, Bachem Holding AG, Tolmar Pharmaceuticals Inc., Debiopharm Group, Sun Pharmaceutical Industries Ltd.
North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonist market in 2023. The regions covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gonadotropin-releasing hormone (GnRH) agonists market consists of sales of triptorelin, buserelin, and nafarelin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gonadotropin-Releasing Hormone (GnRH) Agonist Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gonadotropin-releasing hormone (GnRH) agonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gonadotropin-releasing hormone (GnRH) agonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gonadotropin-releasing hormone (GnRH) agonist market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Leuprorelin; Goserelin; Taltirelin; Histrelin; Other Types
- 2) By Formulation: Injectable; Implants; Oral; Nasal Sprays
- 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
- 4) By Application: Prostate Cancer; Breast Cancer; Endometriosis; Uterine Fibroids; Precocious Puberty; Fertility Treatment; Other Applications
- 5) By End-User: Hospital; Specialty Clinics; Ambulatory Surgical Centers (ASCs); Other End-Users
- Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Sandoz Group AG; Ipsen Pharma
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Characteristics
3. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Trends And Strategies
4. Gonadotropin-Releasing Hormone (GnRH) Agonist Market - Macro Economic Scenario
- 4.1. Impact Of High Inflation On The Market
- 4.2. Ukraine-Russia War Impact On The Market
- 4.3. COVID-19 Impact On The Market
5. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market Size and Growth
- 5.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
- 5.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
- 5.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Segmentation
- 6.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Leuprorelin
- Goserelin
- Taltirelin
- Histrelin
- Other Types
- 6.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Injectable
- Implants
- Oral
- Nasal Sprays
- 6.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.4. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Prostate Cancer
- Breast Cancer
- Endometriosis
- Uterine Fibroids
- Precocious Puberty
- Fertility Treatment
- Other Applications
- 6.5. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Hospital
- Specialty Clinics
- Ambulatory Surgical Centers (ASCs)
- Other End-Users
7. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Regional And Country Analysis
- 7.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 7.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 8.1. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
- Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 8.3. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 8.4. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 9.1. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
- 9.2. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
- 9.3. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
- 9.4. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 10.1. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 10.2. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 10.3. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 11.1. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
- 11.2. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 11.3. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 11.4. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 12.1. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 12.2. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 12.3. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 13.1. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 13.2. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 13.3. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 14.1. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
- 14.2. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 14.3. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 14.4. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 15.1. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
- 15.2. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 15.3. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 15.4. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 16.1. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 16.2. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 16.3. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 17.1. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 17.2. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 17.3. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 18.1. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 18.2. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 18.3. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 19.1. Italy Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 19.2. Italy Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 19.3. Italy Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 20.1. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 20.2. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 20.3. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 21.1. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
- 21.2. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 21.3. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 21.4. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 22.1. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 22.2. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 22.3. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 23.1. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
- 23.2. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 23.3. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 23.4. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 24.1. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
- 24.2. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 24.3. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 24.4. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 25.1. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
- 25.2. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 25.3. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 25.4. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 26.1. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
- 26.2. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 26.3. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 26.4. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 27.1. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 27.2. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 27.3. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 28.1. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
- 28.2. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 28.3. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 28.4. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market
- 29.1. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
- 29.2. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 29.3. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 29.4. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Competitive Landscape And Company Profiles
- 30.1. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Competitive Landscape
- 30.2. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Company Profiles
- 30.2.1. Pfizer Inc.
- 30.2.1.1. Overview
- 30.2.1.2. Products and Services
- 30.2.1.3. Strategy
- 30.2.1.4. Financial Performance
- 30.2.2. AbbVie Inc.
- 30.2.2.1. Overview
- 30.2.2.2. Products and Services
- 30.2.2.3. Strategy
- 30.2.2.4. Financial Performance
- 30.2.3. Takeda Pharmaceutical Company Limited
- 30.2.3.1. Overview
- 30.2.3.2. Products and Services
- 30.2.3.3. Strategy
- 30.2.3.4. Financial Performance
- 30.2.4. Sandoz Group AG
- 30.2.4.1. Overview
- 30.2.4.2. Products and Services
- 30.2.4.3. Strategy
- 30.2.4.4. Financial Performance
- 30.2.5. Ipsen Pharma
- 30.2.5.1. Overview
- 30.2.5.2. Products and Services
- 30.2.5.3. Strategy
- 30.2.5.4. Financial Performance
- 30.2.1. Pfizer Inc.
31. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Other Major And Innovative Companies
- 31.1. Aurobindo Pharma Limited
- 31.2. Cipla Limited
- 31.3. Dr Reddy's Laboratories Ltd.
- 31.4. Intas Pharmaceuticals Ltd.
- 31.5. Ferring Pharmaceuticals
- 31.6. Amneal Pharmaceuticals Inc.
- 31.7. Endo International plc
- 31.8. Lupin Limited
- 31.9. Gland Pharma Limited
- 31.10. Glenmark Pharmaceuticals Ltd.
- 31.11. Zydus Lifesciences Limited
- 31.12. Bachem Holding AG
- 31.13. Tolmar Pharmaceuticals Inc.
- 31.14. Debiopharm Group
- 31.15. Sun Pharmaceutical Industries Ltd.
32. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market Competitive Benchmarking
33. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Gonadotropin-Releasing Hormone (GnRH) Agonist Market
35. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Future Outlook and Potential Analysis
- 35.1 Gonadotropin-Releasing Hormone (GnRH) Agonist Market In 2028 - Countries Offering Most New Opportunities
- 35.2 Gonadotropin-Releasing Hormone (GnRH) Agonist Market In 2028 - Segments Offering Most New Opportunities
- 35.3 Gonadotropin-Releasing Hormone (GnRH) Agonist Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
